SGCB and hypertensive disorder: In 2015, it was reported that the sGC stimulator BAY 41-8543 protected against weight gain and improved the diabetic phenotype in a diet-induced obesity mouse model (Hoffmann et al., 2015), and in a study in 26 patients with diabetes and hypertension, 14 days of treatment with the sGC stimulator praliciguat reduced fasting glucose level and total and LDL cholesterol levels (Hanrahan et al., 2020).